References
  1. Gibbison B, Sheikh A, McShane P, Haddow C, Soar J. Anaphylaxis admissions to UK critical care units between 2005 and 2009. Anaesthesia. 2012;67:833–839.
  2. Lombardo C, Bonadonna P. Hypersensitivity Reactions to Proton Pump Inhibitors. Curr Treat Options Allergy. 2015;2:110–123.
  3. Bonadonna P, Lombardo C, Bortolami O, Bircher A, Scherer K, Barbaud A, et al. Hypersensitivity to proton pump inhibitors: diagnostic accuracy of skin tests compared to oral provocation test. J Allergy Clin Immunol. 2012;130:547–549.
  4. Ward RM, Kearns GL. Proton Pump Inhibitors in Pediatrics. Pediatr Drugs. 2013;15:119–131.
  5. Thomson ABR, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol. 2010;16:2323–2330.
  6. Jordakieva G, Kundi M, Untersmayr E, Pali-Schöll I, Reichardt B, Jensen-Jarolim E. Country-wide medical records infer increased allergy risk of gastric acid inhibition. Nat Commun. 2019;10:3298.
  7. Attwood SE, Ell C, Galmiche JP, Fiocca R, Hatlebakk G, Hasselgren B, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015;41:1162–1174.
  8. Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, et al. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 2019;157:682-691.
  9. Strand DS, Kim D, Peura DA. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver. 2017;11:27-37.
  10. Baird AG, Lawrence JR. Guidelines: is bigger better? A review of SIGN guidelines. BMJ Open. 2014;4:e004278.
  11. Scottish Intercollegiate Guidelines Network. SIGN 50: A guideline developer’s handbook. Accessed September 1, 2022. Available at: https://www.sign.ac.uk/our-guidelines/sign-50-a-guideline-developers-handbook/. Edinburgh: SIGN; 2019.
  12. Diesner SC, Knittelfelder R, Krishnamurthy D, Pali-Schöll I, Gajdzik L, Jensen-Jarolim E, et al. Dose-dependent food allergy induction against ovalbumin under acid-suppression: a murine food allergy model. Immunol Lett. 2008;121:45–51.
  13. Riemer AB, Gruber S, Pali-Schöll I, Kinaciyan T, Untersmayr E, Jensen-Jarolim E. Suppression of gastric acid increases the risk of developing immunoglobulin E-mediated drug hypersensitivity: human diclofenac sensitization and a murine sensitization model. Clin Exp Allergy. 2010;40:486–493.
  14. Mitre E, Susi A, Kropp LE, Schwartz DJ, Gotman GH, Nylund CM. Association Between Use of Acid-Suppressive Medications and Antibiotics During Infancy and Allergic Diseases in Early Childhood. JAMA Pediatr. 2018;172:e180315.
  15. Ramírez E, Cabañas R, Laserna LS, Fiandor A, Tong H, Prior N, et al. Proton pump inhibitors are associated with hypersensitivity reactions to drugs in hospitalized patients: a nested case-control in a retrospective cohort study. Clin Exp Allergy. 2013;43:344–352.
  16. Vega M, Alonso SB, España AP, Teruel SJQ, Fernández SF, Bermejo TB, et al. Treatment with proton pump inhibitors as a cofactor in adverse reactions of patients undergoing oral food immunotherapy: Observational Study. Allergol Imunopathol (Madr). 2021;49:169-172.
  17. Kepil Özdemir S, Yılmaz I, Aydın O, Büyüköztürk S, Gelincik A, Demirtürk M, et al. Immediate-type hypersensitivity reactions to proton pump inhibitors: usefulness of skin tests in the diagnosis and assessment of cross-reactivity. Allergy. 2013;68:1008–1014.
  18. Kepil Özdemir S, Öner Erkekol F, Ünal D, Büyüköztürk S, Gelincik A, Dursun AB, et al. Management of Hypersensitivity Reactions to Proton Pump Inhibitors: A Retrospective Experience. Int Arch Allergy Immunol. 2016;171:54-60.
  19. Laguna JJ, Bogas G, Salas M, Mayorga C, Dionicio J, Gonzalez-Mendiola R, et al. The Basophil Activation Test Can Be of Value for Diagnosing Immediate Allergic Reactions to Omeprazole. J Allergy Clin Immunol Pract. 2018;6:1628-1636.
  20. Abdul Razzak E, Tomás M, Tornero P, Herrero T. Nine cases of allergy to omeprazole. J Investig Allergol Clin Immunol. 2012;22:228–230.
  21. Gamboa PM, Sanz ML, Urrutia I, Jáuregui I, Antépara I, Diéguez I, et al. CD63 expression by flow cytometry in the in vitro diagnosis of allergy to omeprazole. Allergy. 2003;58:538–539.
  22. Lobera T, Navarro B, Del Pozo MD, González I, Blasco A, Escudero R, et al.. Nine cases of omeprazole allergy: cross-reactivity between proton pump inhibitors. J Investig Allergol Clin Immunol. 2009;19:57–60.
  23. Sánchez-Morillas L, Rojas Pérez-Ezquerra P, González Mendiola R, Gómez-Tembleque Ubeda P, Santos Alvarez A, Laguna-Martínez JJ. Eleven cases of omeprazole hypersensitivity: diagnosis and study of cross-reactivity. J Investig Allergol Clin Immunol. 2014;24:130–132.
  24. Sobrevia Elfau MT, Garcés Sotillos M, Ferrer Clavería L, Segura Arazuri N, Monzón Ballarin S, Colás Sanz C. Study of cross-reactivity between proton pump inhibitors. J Investig Allergol Clin Immunol. 2010;20:157–161.
  25. Benito-Garcia F, Chambel M, Morais-Almeida M. Anaphylaxis due to proton pump inhibitors: current understanding and important clinical considerations. Expert Rev Clin Immunol. 2018;14:653–656.
  26. Safe M, Chan WH, Leach ST, Sutton L, Lui K, Krishnan U. Widespread use of gastric acid inhibitors in infants: Are they needed? Are they safe? World J Gastrointest Pharmacol Ther. 2016;7:531–539.
  27. Chang Y-S. Hypersensitivity reactions to proton pump inhibitors. Curr Opin Allergy Clin Immunol. 2012;12:348–353.
  28. Otani IM, Banerji A. Immediate and Delayed Hypersensitivity Reactions to Proton Pump Inhibitors: Evaluation and Management. Current Allergy and Asthma Reports. 2016;16:17.
  29. Bose S, Guyer A, Long A, Banerji A. Evaluation and management of hypersensitivity to proton pump inhibitors. Ann Allergy, Asthma Immunol. 2013;111:452–457.
  30. Tayman C, Mete E, Catal F, Tonbul A. Hypersensitivity reaction to omeprazole in a child. J Investig Allergol Clin Immunol. 2009;19:76–77.
  31. Reyes Balaguer J, Campos Andreu A, Hernández Fernández de Rojas D. Anaphylaxis to proton pump inhibitors. Med Clin (Barc). 2007;128:799.
  32. Baldo BA, Pham NH. Chapter 11: Proton Pump Inhibitors. In: Baldo BA, Pham NH, eds. Drug Allergy. Springer, Cham;2021:521-531.
  33. Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. Pharmacol Res. 2009;59:135-153.
  34. Kollmeier AP, Eddleston J, Zuraw BL, Christiansen SC. Recurrent anaphylaxis linked to pantoprazole. J Allergy Clin Immunol. 2004;114:975-977.
  35. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19:25-35.
  36. Cartee NMP, Wang MM. Binding of omeprazole to protein targets identified by monoclonal antibodies. PLoS One. 2020;15:e0239464.
  37. González P, Soriano V, López P, Niveiro E. Anaphylaxis to proton pump inhibitors. Allergol Immunopathol (Madr). 2002;30:342-343.
  38. Pérez-Ezquerra PR, Morillas LS, Martínez JJ, Fernández GD, Gomez-Tembleque M del P, Alvarez AS, Sanz ML. Anaphylaxis to omeprazole. Cross-reactivity with the other proton pump inhibitors. Allergol Immunopathol (Madr). 2011;39:54.
  39. Vovolis V, Koutsostathis N, Stefanaki E. IgE-mediated anaphylaxis to proton pump inhibitors - cross-reacting study. Allergy. 2008;63:1251-1252.
  40. Confino-Cohen R, Goldberg A. Anaphylaxis to omeprazole: diagnosis and desensitization protocol. Ann Allergy Asthma Immunol. 2006;96:33-36.
  41. Garrido Fernández S, Cumplido JA, Rábano A, Martínez D, Blanco C, Carrillo T. Allergy to proton pump inhibitors: diagnosis and assessment of cross-reactivity. J Investig Allergol Clin Immunol. 2008;18:140-141.
  42. Porcel S, Rodríguez A, Jiménez S, Alvarado M, Hernández J. Allergy to lansoprazole: study of cross-reactivity among proton-pump inhibitors. Allergy. 2005;60:1087-1088.
  43. Galindo PA, Borja J, Feo F, Gómez E, García R, Cabrera M, et al. Anaphylaxis to omeprazole. Ann Allergy Asthma Immunol. 1999;82:52-54.
  44. Natsch S, Vinks MH, Voogt AK, Mees EB, Meyboom RH. Anaphylactic reactions to proton-pump inhibitors. Ann Pharmacother. 2000;34:474-476.
  45. Kepil Özdemir S, Gelincik A, Paksoy N, Köycü Buhari G, Öner Erkekol F, Dursun AB, et al. Analysis of the factors associated with diagnostic skin test positivity in immediate-type hypersensitivity reactions due to proton pump inhibitors. Allergy. 2019;74:1187-1190.
  46. Casciaro M, Navarra M, Inferrera G, Liotta M, Gangemi S, Minciullo PL. PPI adverse drugs reactions: a retrospective study. Clin Mol Allergy. 2019;17:1.
  47. Kepil Özdemir S, Bavbek S. Hypersensitivity reactions to proton-pump inhibitors: Clinical presentation, diagnosis, and management. Allergy Asthma Proc. 2020;41:e37-e44.
  48. Haeney MR. Angio-edema and urticaria associated with omeprazole. BMJ 1992;305:870.
  49. Bowlby HA, Dickens GR. Angioedema and urticaria associated with omeprazole confirmed by drug rechallenge. Pharmacotherapy. 1994;14:119-122.
  50. Ottervanger JP, Phaff RA, Vermeulen EG, Stricker BH. Anaphylaxis to omeprazole. J Allergy Clin Immunol. 1996;97:1413-1414.
  51. Molinero MA, Ballesteros del Río B, de Paz FN, Pérez EF. Immediate anaphylactic shock after the administration of intravenous omeprazol. Rev Clin Esp. 2003;203:216-217.
  52. Ricciardi L, Fedele R, Mazzeo L, Saitta S, Mancuso V, Isola S. Adverse reactions to pantoprazole. Scand J Gastroenterol. 2003;38:800.
  53. Vovolis V, Christogianni K, Koutsostathis N. Immunoglobulin E-mediated anaphylaxis to rabeprazole. J Investig Allergol Clin Immunol. 2010;20:360-361.
  54. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy. 2002;57:45-51.
  55. Stefanaki EC, Vovolis V, Letsa I, Koutsostathis N. Anaphylactic reaction to omeprazole. Am J Gastroenterol. 2008;103:1581-1583.
  56. Perez Pimiento AJ, Prieto Lastra L, Rodrıguez Cabreros MI, Gonzalez Sanchez LA, Mosquera MR, Garcia Cubero A. Hypersensitivity to lansoprazole and rabeprazole with tolerance to other proton pump inhibitors. J Allergy Clin Immunol. 2006;117:707–708.
  57. Tourillon C, Mahe J, Baron A, Lambert A, Yélehé-Okouma M, Veyrac G, Jolliet P. Immediate-Type Hypersensitivity Cross-Reactions to Proton Pump Inhibitors: A Descriptive Study of Data from the French National Pharmacovigilance Database. Int Arch Allergy Immunol. 2019;178:159-166.
  58. Aksu K, Kurt E. Anaphylaxis to lansoprazole with tolerance to omeprazole. Allergol Immunopathol (Madr).2012;40:393-394.
  59. Choi SW, Han JM, Bae YJ, Lee YS, Cho YS, Moon HB, Kim TB. Lessons from two cases of anaphylaxis to proton pump inhibitors. J Clin Pharm Ther. 2012;37:614-616.
  60. Karabacak E, Kutlu A, Aydin E, Ozturk S. Hypersensitivity to lansoprazole with tolerance to other proton pump inhibitors: does cross-reactivity between proton pump inhibitors really exist? Allergol Immunopathol (Madr). 2013;41:136-137.
  61. Turedi O, Sozener ZC, Kendirlinan R, Bavbek S. A Case of Pantoprazole Anaphylaxis with Cross Reactivity to All Proton Pump Inhibitors: Finding a Safe Alternative. Curr Drug Saf. 2017;12:198-200.
  62. Mayorga C, Celik G, Rouzaire P, Whitaker P, Bonadonna P, Rodrigues-Cernadas J,et al. In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2016;71:1103-1134.
  63. Mota I, Gaspar Â, Chambel M, Morais-Almeida M. Anaphylaxis induced by proton pump inhibitors. J Allergy Clin Immunol Pract. 2016;4:535–536.
  64. Demirkan K, Bozkurt B, Karakaya G, Kalyoncu AF. Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature. J Investig Allergol Clin Immunol. 2006;16:203–209.
  65. Pita JS, Azevedo J, Fernandes RA, Loureiro C, Bom AT. Immediate-hypersensitivity reactions to proton pump inhibitors: Experience in a medical department. Ann Allergy Asthma Immunol. 2019;122:204-205.
  66. Kara M, Tanoglu A, Kutlu A, Sirkeci O, Kekilli M. Esomeprazole: a safe alternative to lansoprazole allergy? Iran J Allergy Asthma Immunol. 2014;13:296-297.
  67. Fardet L, Izzedine H, Ciroldi M, Tiev KP, Cabane J. Pantoprazole-induced recurrent anaphylactic shock. Am J Gastroenterol. 2002;97:2933.
  68. Canpolat U, Şahiner L, Aytemir K, Oto A. Allergic reaction to proton pump inhibitor: pantoprazole induced Kounis syndrome. Int J Cardiol. 2012;159:e27-e28.
  69. González-Rubio F, Esteban-Jiménez O, Garcés-Sotillos MD, Colás-Sanz C. Anaphylactic shock due to omeprazole.Gastroenterol Hepatol. 2017;40:20-21.
  70. Yıldız E, Çölkesen F, Sadi Aykan F, Evcev R, Kılınç M, Aytekin G, Arslan Ş. Successful Oral Desensitization to Rabeprazole: A Case Report of a Patient with Duodenal Ulcer. Asthma Allergy Immunol. 2022;20:120-123.
  71. Lin CY, Wang CW, Hui CR, Chang YC, Yang CH, Cheng CY, et al. Delayed-type hypersensitivity reactions induced by proton pump inhibitors: A clinical and in vitro T-cell reactivity study. Allergy. 2018; 73:221–229.
  72. Hammami S, Affes H, Ksouda K, Feki M, Sahnoun Z, Zeghal KM. Étude de l’allergie croisée entre les différents inhibiteurs de la pompe à protons [Study of cross reactivity between proton pump inhibitors]. Therapie. 2013;68:361-368.
  73. Morais P, Baudrier T, Mota A, Cunha AP, Cadinha S, Barros AM, Azevedo F. Nonpigmented fixed drug eruption induced by esomeprazole. Cutan Ocul Toxicol. 2010;29:217-220.
  74. Raison-Peyron N, Minh HB, Peyron JL, Demoly P, Guillot B. Toxidermie photodistribuée induite par les inhibiteurs de la pompe à protons [Photodistributed cutaneous drug reaction induced by proton pump inhibitors]. Therapie. 2005;60:85-87.
  75. Caboni S, Gunera-Saad N, Ktiouet-Abassi S, Berard F, Nicolas JF. Esomeprazole-induced DRESS syndrome. Studies of cross-reactivity among proton-pump inhibitor drugs. Allergy. 2007;62:1342-1343.
  76. Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M, et al; Toxidermies group of the French Society of Dermatology. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol. 2013;168:555-562.
  77. Nantes Castillejo O, Zozaya Urmeneta JM, Valcayo Peñalba A, Martínez-Peñuela Virseda JM. Pustulosis exantemática aguda generalizada inducida por omeprazol [Acute generalized exanthematous pustulosis induced by omeprazole]. Gastroenterol Hepatol. 2008;31:295-298.
  78. Schmitz B, Sorrells T, Glass JS. Acute generalized exanthematous pustulosis caused by pantoprazole. Cutis. 2018;101:e22-e23.
  79. Heaton NR, Edmonds EV, Francis ND, Bunker CB, Bowling JC, Morar N. Fatal toxic epidermal necrolysis due to lansoprazole. Clin Exp Dermatol. 2004;29:612-613.
  80. Fracaroli TS, Miranda LQ, Sodré JL, Chaves M, Gripp A. Toxic epidermal necrolysis induced by lansoprazole. An Bras Dermatol. 2013;88:117-120.
  81. Casacci M, Lebas D, Decamps F, Fourrier F, Delaporte E. Toxic epidermal necrolysis due to omeprazole. Eur J Dermatol. 2006;16:699-700.
  82. Thakor AS, Burke A, Handfield-Jones S, Sinha A, Palmer M, Burns A. Toxic epidermal necrolysis and neutropaenia: complications of omeprazole. Australas J Dermatol. 2009;50:207-210.
  83. Brajon D, Menetre S, Waton J, Poreaux C, Barbaud A. Non-irritant concentrations and amounts of active ingredient in drug patch tests. Contact Dermatitis. 2014;71:170-175.
  84. Barbaud A, Castagna J, Soria A. Skin tests in the work-up of cutaneous adverse drug reactions: A review and update. Contact Dermatitis. 2022;86:344-356.
  85. Kim D, Kang H. Proton pump inhibitor-induced vitiligo following airborne occupational sensitization. Contact Dermatitis. 2021;85:595-596.
  86. DeKoven JG, Yu AM. Occupational Airborne Contact Dermatitis From Proton Pump Inhibitors. Dermatitis. 2015;26:287-290.
  87. Ghatan PH, Marcusson-Ståhl M, Matura M, Björkheden C, Lundborg P, Cederbrant K. Sensitization to omeprazole in the occupational setting. Contact Dermatitis. 2014;71:371-375.